周六报道，iTeos Therapeutics宣布了葛兰素史克赞助的GALAXIES Lung-201 II期平台研究的后续中期数据，用于Belrestotug+Dostarlimab Doublet治疗既往未经治疗、不可切除、局部晚期或转移性PD-L1高非小细胞肺癌

2024-09-16 16:47

Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose.
>30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy.
Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations.
GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting